Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group

In English

Författare

  • S A Narod
  • H Risch
  • R Moslehi
  • A Dørum
  • S Neuhausen
  • Håkan Olsson
  • D Provencher
  • P Radice
  • G Evans
  • S Bishop
  • J S Brunet
  • B A Ponder
Visa allt

Summary, in English

BACKGROUND: Women with mutations in either the BRCA1 or the BRCA2 gene have a high lifetime risk of ovarian cancer. Oral contraceptives protect against ovarian cancer in general, but it is not known whether they also protect against hereditary forms of ovarian cancer.

METHODS: We enrolled 207 women with hereditary ovarian cancer and 161 of their sisters as controls in a case-control study. All the patients carried a pathogenic mutation in either BRCA1 (179 women) or BRCA2 (28 women). The control women were enrolled regardless of whether or not they had either mutation. Lifetime histories of oral-contraceptive use were obtained by interview or by written questionnaire and were compared between patients and control women, after adjustment for year of birth and parity.

RESULTS: The adjusted odds ratio for ovarian cancer associated with any past use of oral contraceptives was 0.5 (95 percent confidence interval, 0.3 to 0.8). The risk decreased with increasing duration of use (P for trend, <0.001); use for six or more years was associated with a 60 percent reduction in risk. Oral-contraceptive use protected against ovarian cancer both for carriers of the BRCA1 mutation (odds ratio, 0.5; 95 percent confidence interval, 0.3 to 0.9) and for carriers of the BRCA2 mutation (odds ratio, 0.4; 95 percent confidence interval, 0.2 to 1.1).

CONCLUSIONS: Oral-contraceptive use may reduce the risk of ovarian cancer in women with pathogenic mutations in the BRCA1 or BRCA2 gene.

Publiceringsår

1998-08-13

Språk

Engelska

Sidor

8-424

Publikation/Tidskrift/Serie

New England Journal of Medicine

Volym

339

Issue

7

Dokumenttyp

Artikel i tidskrift

Förlag

Massachusetts Medical Society

Ämne

  • Cancer and Oncology

Nyckelord

  • Adult
  • Aged
  • BRCA2 Protein
  • Case-Control Studies
  • Contraceptives, Oral
  • Female
  • Genes, BRCA1
  • Germ-Line Mutation
  • Humans
  • Middle Aged
  • Neoplasm Proteins
  • Nuclear Family
  • Odds Ratio
  • Ovarian Neoplasms
  • Transcription Factors

Status

Published

Forskningsgrupp

  • Lund Melanoma Study Group

ISBN/ISSN/Övrigt

  • ISSN: 0028-4793